The earnings call highlighted strong sales growth across all segments, improved free cash flow, and positive performance in the pharmacy and healthcare segments. However, it also noted challenges with declining retail sales in the U.S. and a significant decline in adjusted EPS. Despite these challenges, the company remains focused on executing its turnaround strategy.

Company Guidance

During the Walgreens Boots Alliance earnings call for Q1 2025, the management provided detailed guidance on several key metrics. Sales increased by 6.9% on a constant currency basis, with growth across all segments. The adjusted earnings per share (EPS) was reported at $0.51, reflecting a 23% decline year-over-year, primarily due to prior year sale-leaseback gains and lower Cencora equity income. Despite these challenges, the U.S. Retail Pharmacy segment saw a notable comparable sales growth of 8.5%, driven by pharmacy performance, although retail sales declined. In the U.S. Healthcare segment, sales rose by 12%, with VillageMD and Shields showing strong performance. The company achieved significant progress in its Footprint Optimization Program, closing about 70 stores in the quarter and planning for nearly 450 more by the end of 2025. For the fiscal year, Walgreens Boots Alliance reaffirmed its adjusted EPS guidance of $1.40 to $1.80, while also expecting retail comp sales to decline approximately 4% to 5%. The company emphasized its focus on stabilizing and turning around its business by improving drug procurement, optimizing store operations, and advancing its pharmacy services, with a strong emphasis on cost management and cash flow improvement.

Sales Growth Across All Segments

Sales increased 6.9% on a constant currency basis with growth across all segments.

Improved Free Cash Flow

Free cash flow improved due to decreased capital expenditures and higher adjusted operating income.

U.S. Pharmacy Services Performance

U.S. Pharmacy Services performed better than expectations with higher margin for COVID-19 vaccines.

International Business Growth

Total sales in the International segment grew 6.5% with Germany wholesale increasing 11.3% and Boots UK up 4.5%.

Healthcare Segment Growth

U.S. Healthcare sales of $2.2 billion increased 12%, with strong performance from VillageMD and Shields.

---

Walgreens Boots Alliance (WBA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WBA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 11, 2018	2018 (Q4)	- / 1.48	1.31	12.98% (+0.17)	―	―
Dec 20, 2018	2019 (Q1)	- / 1.46	1.28	14.06% (+0.18)	―	―
Apr 02, 2019	2019 (Q2)	- / 1.64	1.73	-5.20% (-0.09)	―	―
Jun 27, 2019	2019 (Q3)	- / 1.47	1.53	-3.92% (-0.06)	―	―
Oct 28, 2019	2019 (Q4)	- / 1.43	1.48	-3.38% (-0.05)	―	―
Jan 08, 2020	2020 (Q1)	- / 1.37	1.46	-6.16% (-0.09)	―	―
Apr 02, 2020	2020 (Q2)	- / 1.52	1.64	-7.32% (-0.12)	―	―
Jul 09, 2020	2020 (Q3)	- / 0.83	1.47	-43.54% (-0.64)	―	―
Oct 15, 2020	2020 (Q4)	- / 1.02	1.43	-28.67% (-0.41)	―	―
Jan 07, 2021	2021 (Q1)	- / 1.22	1.37	-10.95% (-0.15)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

WBA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 10, 2025	$9.22	$11.76	+27.55%
Oct 15, 2024	$8.73	$10.11	+15.81%
Jun 27, 2024	$14.84	$11.55	-22.17%
Mar 28, 2024	$19.65	$20.28	+3.21%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---